Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer Oshita F; Ohe M; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yamashita K; Nakayama Y; Yamada KBr J Cancer 2010[Oct]; 103 (9): 1325-30BACKGROUND: Current international guidelines recommend the use of platinum-based chemotherapy with thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with unresectable stage IIIA or IIIB NSCLC were treated with nedaplatin (NP) at 50 mg m(-2) and irinotecan (CPT) at 60 mg m(-2) on days 1 and 8 every 4 weeks for two to four cycles with concurrent TRT (2 Gy per day, total 60 Gy). RESULTS: All 35 patients were able to receive a total of 60 Gy. Adverse effects and events in chemotherapy with TRT were grade 3 or 4 anaemia, neutropenia and thrombocytopenia, which occurred in 3.0%, 32.8% and 6.0% of patients, respectively. There was no grade 3 pneumonitis or oesophagitis. Adverse effects and events in chemotherapy alone were mild. There was no treatment-related death. An overall response rate was 94.3%. The median progression-free and overall survivals were 13.0 and 36.0 months, respectively. The 5-year disease-free and overall survival rates were 25.7% and 40.0%, respectively. CONCLUSION: NP and CPT treatment with concurrent TRT is effective and safe for patients with unresectable, locally advanced NSCLC.|Adult[MESH]|Aged[MESH]|Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use[MESH]|Camptothecin/administration & dosage/*analogs & derivatives[MESH]|Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology/*radiotherapy[MESH]|Combined Modality Therapy[MESH]|Disease-Free Survival[MESH]|Female[MESH]|Humans[MESH]|Irinotecan[MESH]|Lung Neoplasms/*drug therapy/mortality/pathology/*radiotherapy[MESH]|Male[MESH]|Organoplatinum Compounds/*administration & dosage[MESH]|Recurrence[MESH] |